The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | An insight into the prevalence of various subtypes of MGUS in the iStopMM study
Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, shares some insights into the prevalence of various subtypes of monoclonal gammopathy of undetermined significance (MGUS) in the iStopMM study (NCT03327597), and factors influencing these. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Celgene: Research Funding; Amgen: Research Funding.
